{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-123703","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.747857+00:00","generated_at":"2026-05-30T02:47:54.652497+00:00","sec_items":["5.07","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Akari shareholders approve Peak Bio merger; close targeted Nov 13, Nasdaq listing risk seen removed","bullets":["All six merger proposals passed with ~99% of vote; 14.6B shares for Merger Allotment.","Transaction expected to close on November 13, 2024.","Upon close, Akari expects to remedy Nasdaq shareholder deficiency, removing delisting risk.","All-stock merger structured for ~50/50 ownership between Akari and Peak Bio holders.","Combined entity to operate as Akari Therapeutics, trading as AKTX on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-123703","json":"https://secwatch.observer/filing/0000950170-24-123703.json","markdown":"https://secwatch.observer/filing/0000950170-24-123703.md","text":"https://secwatch.observer/filing/0000950170-24-123703.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024123703/0000950170-24-123703-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024123703/aktx-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:47:54.652497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}